Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul-Dec;23(12):1135-1152.
doi: 10.1080/14737159.2023.2267977. Epub 2023 Dec 15.

An update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections

Jeffrey D Jenks  1   2 , P Lewis White  3 , Sarah E Kidd  4   5 , Tyler Goshia  6 , Stephanie I Fraley  6 , Martin Hoenigl  7   8 , George R Thompson 3rd  9   10   11
Affiliations
Review

An update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections

Jeffrey D Jenks et al. Expert Rev Mol Diagn. 2023 Jul-Dec.

Abstract

Background: Invasive fungal infections cause millions of infections annually, but diagnosis remains challenging. There is an increased need for low-cost, easy to use, highly sensitive and specific molecular assays that can differentiate between colonized and pathogenic organisms from different clinical specimens.

Areas covered: We reviewed the literature evaluating the current state of molecular diagnostics for invasive fungal infections, focusing on current and novel molecular tests such as polymerase chain reaction (PCR), digital PCR, high-resolution melt (HRM), and metagenomics/next generation sequencing (mNGS).

Expert opinion: PCR is highly sensitive and specific, although performance can be impacted by prior/concurrent antifungal use. PCR assays can identify mutations associated with antifungal resistance, non-Aspergillus mold infections, and infections from endemic fungi. HRM is a rapid and highly sensitive diagnostic modality that can identify a wide range of fungal pathogens, including down to the species level, but multiplex assays are limited and HRM is currently unavailable in most healthcare settings, although universal HRM is working to overcome this limitation. mNGS offers a promising approach for rapid and hypothesis-free diagnosis of a wide range of fungal pathogens, although some drawbacks include limited access, variable performance across platforms, the expertise and costs associated with this method, and long turnaround times in real-world settings.

Keywords: Molecular diagnostics; PCR; digital PCR; high resolution melt; invasive fungal disease; metagenomics; next-generation sequencing; polymerase chain reaction.

PubMed Disclaimer

Conflict of interest statement

JDJ received research funding from Astellas, F2G, and Pfizer – all outside of the submitted work. PLW performed diagnostic evaluations and received meeting sponsorship from Bruker, Dynamiker, and Launch Diagnostics; Speaker’s fees, expert advice fees and meeting sponsorship from Gilead; Speaker and expert advice fees from F2G and speaker fees MSD and Pfizer: Speaker’s fees and performed diagnostic evaluations for Associates of Cape Cod and IMMY. Speakers’ fees from Qiagen. Expert advice fees from Mundipharma – all outside of the submitted work. SIF is a scientific cofounder, director, and advisor of MelioLabs, Inc., and has an equity interest in the company. NIAID award number R01AI134982 has been identified for conflict of interest management based on the overall scope of the project and its potential benefit to MelioLabs, Inc.; however, the research findings included in this particular publication may not necessarily relate to the interests of MelioLabs, Inc. The terms of this arrangement have been reviewed and approved by the University of California, San Diego, in accordance with its conflict of interest policies. MH received research funding from Gilead, Astellas, MSD, IMMY, Mundipharma, Scynexis, F2G and Pfizer – all outside of the submitted work. GRT received research and consulting fees from Astellas, Amplyx, Cidara, F2G, Mayne, Melinta, Mundipharma, Scynexis, and served on the DRC for Pfizer – all outside of the submitted work. All other authors declare no conflict of interest.

References

    1. Bongomin F, Gago S, Oladele RO, et al. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017. Oct 18;3(4). - PMC - PubMed
    1. Dodd PJ, Shaweno D, Ku CC, et al. Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics. Nat Commun. 2023. Mar 24;14(1):1639. - PMC - PubMed
    1. Organization WH. Home/ Health Topics/ HIV/AIDS. .
    1. Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014. Jun;20(6):872–80. - PubMed
    1. Choi JK, Cho SY, Yoon SS, et al. Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of “RISK” Study. Biol Blood Marrow Transplant. 2017. Oct;23(10):1773–1779. - PubMed

Publication types

Substances